On the basis of the diagnosis, the market is segmented into Computed Tomography (CT),
Magnetic resonance imaging (MRI), tissue biopsy, and others.
On the basis of the treatment, the market is segmented into surgery, antifungal drugs,
amphotericin B therapy, and others. The antifungal drugs is further categorized into
posaconazole, isavuconazole, voriconazole, fluconazole, and flucytosine, and others.
On the basis of the end-user, the market is segmented into hospitals & clinics, medical
institutes, research organization, and others.
Browse Full Reports @ https://www.marketresearchfuture.com/reports/mucormycosis-
market-5440
Regional Analysis:
The Global Mucormycosis Market consists of countries namely the Americas, Europe, Asia
Pacific, and the Middle East and Africa.
The Americas dominate the global mucormycosis market owing to a well-developed
healthcare sector and huge patient population for mucormycosis. Many antifungal drugs
have lost their patients during the last few years such as Terbinafine products like Lamisil
lost their patient in 2017. As there is limited oral preparation in the market, development
and licensing of new drugs in the market is the huge opportunity for the development of the
market during the forecasted period.
Europe is the second largest market for the global mucormycosis owing to the
advancements in the technology of the surgical devices along with the rising occurrence of
fungal infections among the patients. The European government introduced incentives to
help simplify the improvement of anti-infective drugs and dropping the risk and cost of
manufacturers. Some other factors driving the market include the growing percentage of
diabetes mellitus population mainly in the developed countries of Europe. The average
diabetes prevalence rate in Europe is 8.6% of the adult population.
Asia Pacific is the fastest growing region for antifungal treatment due to increasing
prevalence of HIV, and huge untapped growth opportunities for the development of the
market. Every year, approximately 7.1% of the Korean population receives treatment for
fungal diseases. Therefore, further research is needed to understand and monitor the
prevalence of mycoses to establish management policies to reduce the burden of fungal
diseases.
TABLE OF CONTENT
Chapter 1. Report Prologue
Chapter 2. Market Introduction
2.1 Definition
2.2 Scope Of The Study
2.2.1 Research Objective
2.2.2 Assumptions
2.2.3 Limitations
Chapter 3. Research Methodology
3.1 Introduction
3.2 Primary Research
3.3 Secondary Research
3.4 Market Size Estimation
Chapter 4. Market Dynamics
4.1 Drivers
4.2 Restrains
4.3 Opportunities
4.4 Challenges
4.5 Macroeconomic Indicators
4.6 Treatment Trends & Assessment
Chapter 5. Market Factor Analysis
… Continued!